Treatment of breast cancer with trastuzumab is complicated by cardiotoxicity in up to 34% of the patients. In most patients, trastuzumab-induced cardiotoxicity (TIC) is reversible: left ventricular ...

Cardiotoxicity of Trastuzumab in Clinical Practice Published July 5, 2007 N Engl J Med 2007;357: 94 - 95 DOI: 10.1056/NEJMc070065 ...

Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible Authors: Eliza A. Hawkes, Alicia F.C. Okines, Chris Plummer, and David Cunningham Authors Info & Affiliations Publication: ...

It had been thought that such chemotherapy-induced cardiotoxicity became evident soon after treatment, but a Danish team has now shown that it can take months, or even years, to manifest itself.

Novel formulations of anthracycline analogs have been developed, but few have less cardiotoxicity or better cytotoxicity than that of doxorubicin. [109, 110] Those that do appear to be less ...

Rosiglitazone and Cardiotoxicity — Weighing the Evidence Author: David M. Nathan, M.D. Author Info & Affiliations Published July 5, 2007 N Engl J Med 2007;357: 64 - 66 ...

These results are in line with a previous study that also looked at using lisinopril or carvedilol and showed both could help improve cardiotoxicity-free survival among anthracycline-treated ...

Specifically, they are less effective at predicting cardiotoxicity, wherein a drug damages the heart. This is important because one-third of drugs withdrawn from testing are pulled due to ...

Access free, up-to-date clinical references regarding cardiotoxicity management in patients with HER2-positive breast cancer. Healio's Clinical Guidance content provides valuable insights for ...